ASND

Ascendis Pharma A/S is a healthcare company operating in the biotechnology industry. With a market capitalization of $13.02 billion and annual revenues exceeding $646 million, the company has established itself as a significant player in its sector. Its workforce comprises approximately 1,017 employees. Financially, Ascendis Pharma A/S demonstrates mixed results. The company's gross margin stands at 86.8%, while its operating margin is 5.1%. Conversely, net income and EBITDA are negative, totaling -$232.9 million and -$133.7 million, respectively. The company's free cash flow is also in the red, amounting to -$64.4 million. Its balance sheet reveals $539.1 million in cash reserves, which contrasts with its $813.6 million debt load. The return on assets (ROA) stands at -7.7%. Valuation metrics paint a complex picture for Ascendis Pharma A/S. With a forward P/E ratio of 54.53 and price to sales ratio of 20.14, the company's stock appears overvalued relative to its financial performance. The revenue growth rate is substantial, increasing by 269.4% year-over-year, but earnings growth is not available. Dividend yield is also N/A.